Assessment of HIV disease progression before and after initiation of antiretroviral therapy by CD4 & CD8 T-lymphocyte count and viral load assay
DOI:
https://doi.org/10.3329/bsmmuj.v6i1.29084Keywords:
Anti-retroviral therapy, HIV, CD4, CD8, T-lymphocyte count, Viral loadAbstract
Backgrounds: As there is no published data regarding the response to Anti-retroviral therapy (ART) among HIV patients from Bangladesh. The present study was designed to determine the immunological and virological responses of HIV infected Bangladeshi adults starting ART. Objectives: To monitor the changes of CD4 and CD8 T-lymphocyte count and Viral load (VL) before and after three and six months of starting ART.
Methods: 20 symptomatic HIV infected patients with CD4 T-lymphocyte count of <350 cells/µ] of blood were initiated ART.CD4 and CDS T-lymphocyte counts were estimated by Flowcytometer and VL was dete1mined by real-time PCR technique.
Results: The mean CD4 T-lymphocyte count among the sn1dy patients were 177±127 cells/µl before initiation of ART. After ART initiation, their mean CD4 count increased significantly to 368±181 and 452±183 cellshll after three and six months respectively (P<0.0001).The mean CDS T-lymphocyte counts were 901±650 cells/µ! before initiation of ART, which increased to I 085±393 and 1121±372 cells/µl after three and six months respectively after ART initiation (P>0.05). Before ART initiation, the mean VL was 5.25±1.19 log10 (copies/ml) among the study population which became undetectable in 15 (75%) patients after three months of ART and in another 2 (10%) patients after 6 months of ART initiation.
Conclusion: Our study concluded that, ART is effective in slowing the progression of HIV infection to AIDS with good immunological and virological outcome among the ART initiators.
Downloads
324
64
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2016 Sahina Tabassum, S.M. Rashed-ul Islam, Afzalun Nessa, Munira Jahan, Saif Ullah Munshi

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.